{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:33:52Z","timestamp":1775752432816,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jinf.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T14:40:01Z","timestamp":1467384001000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis"],"prefix":"10.1016","volume":"73","author":[{"given":"Pippa J.","family":"Newton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2016.06.001_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.36.4.442","article-title":"Treatment of pulmonary aspergillosis","volume":"36","author":"Kelmenson","year":"1959","journal-title":"Dis Chest"},{"issue":"Suppl. 3","key":"10.1016\/j.jinf.2016.06.001_bib2","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib3","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.ijid.2009.07.011","article-title":"Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases","volume":"14","author":"Nam","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2016.06.001_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01739009","article-title":"Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients","volume":"22","author":"Verweij","year":"1994","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2016.06.001_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0163-4453(91)90954-Q","article-title":"The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B","volume":"22","author":"Van't Wout","year":"1991","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2016.06.001_bib6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jinf.2016.06.001_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Randomised comparison of voriconazole and amphotericin B in primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jinf.2016.06.001_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/jac\/dks521","article-title":"High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia","volume":"68","author":"Lewis","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2016.06.001_bib12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1128\/AAC.01283-12","article-title":"New insight into amphotericin B resistance in Aspergillus terreus","volume":"57","author":"Blum","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2016.06.001_bib13","article-title":"Is Aspergillus nidulans susceptible to all antifungal agents? In\u00a0vitro activity of an updated panel of antifungal agents against 63 clinical isolates","author":"Palaez","year":"2009","journal-title":"Clin Microbiol Infec"},{"key":"10.1016\/j.jinf.2016.06.001_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-199809000-00004","article-title":"Aspergillus nidulans infection in chronic granulomatous disease","volume":"77","author":"Segal","year":"1998","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jinf.2016.06.001_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of Aspergillus","volume":"178","author":"Alastruey-Izquierdo","year":"2014","journal-title":"Mycopathologia"},{"issue":"5","key":"10.1016\/j.jinf.2016.06.001_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jiac.2014.01.003","article-title":"Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan","volume":"20","author":"Kikuchi","year":"2014","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2016.06.001_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus: a growing public health concern","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/cid\/cit321","article-title":"Voriconazole resistance in Aspergillus fumigatus \u2013 should we be concerned?","volume":"57","author":"Denning","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ps.3567","article-title":"Fungicides and triazole resistance in Aspergillus","volume":"70","author":"Bowyer","year":"2014","journal-title":"Pest Manag Sci"},{"key":"10.1016\/j.jinf.2016.06.001_bib20","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/jac\/dkv177","article-title":"High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients","volume":"70","author":"Fuhren","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2016.06.001_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","author":"Verweij","year":"2015","journal-title":"Drug Res Updat"},{"key":"10.1016\/j.jinf.2016.06.001_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1744-313X.2006.00616.x","article-title":"Cytokine profiling of pulmonary aspergillosis","volume":"33","author":"Sambatakou","year":"2006","journal-title":"Int J Immunogenetics"},{"issue":"8","key":"10.1016\/j.jinf.2016.06.001_bib23","doi-asserted-by":"crossref","first-page":"O480","DOI":"10.1111\/1469-0691.12473","article-title":"A prominent role for IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis","volume":"20","author":"Smith","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2016.06.001_bib24","doi-asserted-by":"crossref","first-page":"O960","DOI":"10.1111\/1469-0691.12643","article-title":"Reduced expression of TLR3, TLR10 and TREM1 by macrophages in CCPA, and novel genetic associations of VEGFA, DENND1B and PLAT with this disease","volume":"20","author":"Smith","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2016.06.001_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","article-title":"Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4","volume":"55","author":"Bellocchio","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2016.06.001_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1749-8090-8-180","article-title":"Surgery for chronic pulmonary aspergillosis, risk stratification and recurrence \u2013 a National Centre's experience","volume":"8","author":"Farid","year":"2013","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.jinf.2016.06.001_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis \u2013 rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Resp J"},{"issue":"Suppl. 1","key":"10.1016\/j.jinf.2016.06.001_bib28","article-title":"KDIGO 2012A Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney International"},{"issue":"Suppl. 1","key":"10.1016\/j.jinf.2016.06.001_bib29","article-title":"KDIGO 2012B Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney International"},{"key":"10.1016\/j.jinf.2016.06.001_bib30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis; a longitudinal analysis","volume":"57","author":"Al-shair","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome of invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib32","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/497126","article-title":"The strategy of following voriconazole versus amphotericin B with other licensed antifungal therapy for primary therapy of invasive aspergillosis: impact of other therapies on outcome","volume":"41","author":"Patterson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib33","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jinf.2016.06.001_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Brit J Haem"},{"key":"10.1016\/j.jinf.2016.06.001_bib36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomised, double-blind comparative trial evaluating the safety of liposomal Amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2016.06.001_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/17425255.2015.1042363","article-title":"A double-blinded placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity","volume":"11","author":"Karimzadeh","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:23:24Z","timestamp":1759008204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445316301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0163445316301219"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2016.06.001","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}